South Korea to receive 20 million vaccine doses from Moderna
Moderna has agreed to supply 20 million doses of the COVID-19 vaccine to South Korea in the second quarter of 2021.
South Korea is currently facing a virus spike as the country reported 1,046 more cases during the past 24 hours, raising the total caseload to 58,725. The country also recorded 40 more fatalities from the deadly virus, raising the death toll to 859.
The country has reached an agreement with Johnson & Johnson’s Janssen and Pfizer and will purchase 20 million doses each from AstraZeneca, Pfizer, and Moderna, enough for 44 million people. However, after the Moderna deal, South Korea will be able to secure vaccine doses for 56 million.
EU to buy additional 100 million doses of Pfizer-BioNtech vaccine
The European Union purchased an additional 100 million doses of Pfizer and BioNTech’s COVID-19 vaccine, bringing the total to 300 million doses.
Under the terms of agreement, the two firms have committed to rapidly deliver 200 million doses after regulatory approval for $19.06 each.
Both the Pfizer and Moderna vaccines require two doses per person. In total, the EU has booked nearly 1.3 billion vaccines in deals with PfizerBioNTech, Moderna, Johnson & Johnson, AstraZeneca-Oxford, Sanofi-GSK and CureVac, and has options to purchase an additional 660 million.
The United Kingdom is expected to approve the Oxford-AstraZeneca COVID-19 vaccine by this week.
AstraZeneca and the University of Oxford’s COVID-19 vaccine is expected to be approved for use in the United Kingdom soon.
The AstraZeneca vaccine would likely be available in the coming week once approved by the regulator.
The Oxford-AstraZeneca vaccine candidate would allow the country to significantly increase its inoculation program.